ArticleBMJ (Clinical research ed.)2018

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.

Antonios Douros et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.